Nature Communications (May 2021)
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
- Stéphane Le Vu,
- Gabrielle Jones,
- François Anna,
- Thierry Rose,
- Jean-Baptiste Richard,
- Sibylle Bernard-Stoecklin,
- Sophie Goyard,
- Caroline Demeret,
- Olivier Helynck,
- Nicolas Escriou,
- Marion Gransagne,
- Stéphane Petres,
- Corinne Robin,
- Virgile Monnet,
- Louise Perrin de Facci,
- Marie-Noelle Ungeheuer,
- Lucie Léon,
- Yvonnick Guillois,
- Laurent Filleul,
- Pierre Charneau,
- Daniel Lévy-Bruhl,
- Sylvie van der Werf,
- Harold Noel
Affiliations
- Stéphane Le Vu
- Infectious Diseases Division, Santé publique France
- Gabrielle Jones
- Infectious Diseases Division, Santé publique France
- François Anna
- Unit of Molecular Virology and Vaccinology, Virology Department, Theravectys, Institut Pasteur
- Thierry Rose
- Unit of Lymphocyte Cell Biology, Immunology Department, INSERM 1221, Institut Pasteur
- Jean-Baptiste Richard
- Data Sciences Division, Santé publique France
- Sibylle Bernard-Stoecklin
- Infectious Diseases Division, Santé publique France
- Sophie Goyard
- Unit of Lymphocyte Cell Biology, Immunology Department, INSERM 1221, Institut Pasteur
- Caroline Demeret
- Unit of Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris-Diderot, Institut Pasteur
- Olivier Helynck
- Unit of Chemistry and Biocatalysis, UMR 3523 CNRS, Institut Pasteur
- Nicolas Escriou
- Innovation Laboratory: Vaccines, Institut Pasteur
- Marion Gransagne
- Innovation Laboratory: Vaccines, Institut Pasteur
- Stéphane Petres
- Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur
- Corinne Robin
- Cerba Healthcare Division, Cerba Xpert
- Virgile Monnet
- Eurofins Biomnis Sample Library, Eurofins Biomnis
- Louise Perrin de Facci
- ICAReB Biobanking Platform, Center for Translational Science, Institut Pasteur
- Marie-Noelle Ungeheuer
- ICAReB Biobanking Platform, Center for Translational Science, Institut Pasteur
- Lucie Léon
- Regional Office—French Caribbean, Santé publique France
- Yvonnick Guillois
- Regional Office—Brittany, Santé publique France
- Laurent Filleul
- Regional Office—Nouvelle Aquitaine, Santé publique France
- Pierre Charneau
- Unit of Molecular Virology and Vaccinology, Virology Department, Theravectys, Institut Pasteur
- Daniel Lévy-Bruhl
- Infectious Diseases Division, Santé publique France
- Sylvie van der Werf
- Unit of Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris-Diderot, Institut Pasteur
- Harold Noel
- Infectious Diseases Division, Santé publique France
- DOI
- https://doi.org/10.1038/s41467-021-23233-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 7
Abstract
The percentage of national populations infected during the first stages of the COVID-19 pandemic are unclear owing to limited early testing. Here the authors provide a nation-wide prevalence study of SARS-CoV-2 antibodies in France from the first wave of COVID-19 in 2020, including stratification based on age, sex and region.
